Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 15 Aug 2017 Status changed from recruiting to completed.
- 06 Dec 2016 Results (n=14) assessing safety and tolerability of Elotuzumab presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (2016).